Stockreport

Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal canc...

AnaptysBio, Inc.  (ANAB) 
Last anaptysbio, inc. earnings: 3/2 08:45 am Check Earnings Report
US:NASDAQ Investor Relations: ir.anaptysbio.com/investor-relations
PDF New treatment options are needed for patients facing negative impacts to quality-of-life with current standard of care Additional registrational studies of dostarlima [Read more]